Trials / Completed
CompletedNCT02732665
Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma
Sensitivity and Specificity of Glycosaminoglycan Scores in the Diagnosis of Early Progression in Advanced Renal Cell Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Jens Nielsen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, glycosaminoglycan (GAG) profiling in subjects diagnosed with metastatic renal cell carcinoma (mRCC) is hypothesized to be useful in monitoring drug response and predict radiological response. To this end, glycosaminoglycan scores based on longitudinal samples of plasma and urine in prospectively enrolled patients will be correlated to radiological response to first-line therapy based on current standard-of-care. A positive correlation indicates that glycosaminoglycan scores can successfully detect patients that are not responding to treatment before the scheduled follow-up in which radiological imaging is performed. Data on the extent of metastasis (number of metastatic sites) will be collected to assess whether glycosaminoglycans correlate accordingly.
Conditions
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2020-12-01
- Completion
- 2021-02-01
- First posted
- 2016-04-11
- Last updated
- 2023-04-05
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02732665. Inclusion in this directory is not an endorsement.